Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Therapy (Adebrelimab) in SNF2 Subtype HR+/HER2- Metastatic Breast Cancer
NCT05205200Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2022
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in breast cancer, sponsored by Fudan University. Started Jun 2022; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05205200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205200.